This summary was created by AI, based on 1 opinions in the last 12 months.
Experts agree that Natera, a biotech company that specializes in accurate cancer testing, is a fast-growing company with the potential to become cash-flow positive this year. With its innovative technology and promising future prospects, it is garnering positive attention from investors and experts alike.
Natera is a American stock, trading under the symbol NTRA-Q on the NASDAQ (NTRA). It is usually referred to as NASDAQ:NTRA or NTRA-Q
In the last year, 1 stock analyst published opinions about NTRA-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Natera.
Natera was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Natera.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Natera In the last year. It is a trending stock that is worth watching.
On 2024-10-31, Natera (NTRA-Q) stock closed at a price of $120.96.
A biotech that does, among other things, cancer testing which is very accurate.. She just bought it. Is growing fast and expects it to be cash-flow positive this year.